Thrombophilia References

References

  1. National Blood Clot Alliance, “https://www.stoptheclot.org/antithrombin-deficiency

  2. U.S. National Library of Medicine: Genetics Home Reference, “Your Guide to Understanding Genetic Conditions: Hereditary Antithrombin Deficiency,” https://ghr.nlm.nih.gov/condition/hereditary-antithrombin-deficiency

  3. Heit, J.A.,et. al., “The Epidemiology of Venous Thromboembolism,” J of Thromb Thrombolysis, 2016; 41: 3-14.

  4. Centers for Disease Control and Prevention, “Leading Causes of Death,” https://www.cdc.gov/nchs/fastats/leading-causes-of-death

  5. Centers for Disease Control and Prevention, “Venous Thromboembolism (Blood Clots): Data and Statistics,” https://www.cdc.gov/ncbddd/dvt/data.html

  6. National Blood Clot Alliance, “Hospitalization: A Major Risk Factor for Dangerous Blood Clots,” https://www.stoptheclot.org/spreadtheword/wp-content/uploads/2016/06/Hospitalization-Infographic.pdf

  7. Heit, J.A., et. al., “The Epidemiology of Venous Thromboembolism,” J of Thromb Thrombolysis, 2016; 41: 3-14.

  8. Bates, S., et. al., “Guidance for the treatment and prevention of obstetric-associated venous thromboembolism,” J Thromb Thrombolysis (2016) 41:92–128

  9. Schick, P., Medscape, “Hereditary and Acquired Hypercoagulability Workup: Laboratory Studies,” May 26,2016. https://emedicine.medscape.com/article/211039-workup

10. Connors, J., “Thrombophilia Testing and Venous Thrombosis,” N Engl J Med 2017;377:1177-87.


11. National Blood Clot Alliance, “https://www.stoptheclot.org/antithrombin-deficiency

12. Ornstein, D., “Cardiology Update: Factor V Leiden,” Circulation. 2003;107:e94-e97.


13. Ibid.

14. Ibid.

15. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ, Whiteman MK, MMWR Recomm Rep. 2016 Jul 29;65(3):1-103. doi: 10.15585/mmwr.rr6503a1. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.

16. Ornstein, D., “Cardiology Update: Factor V Leiden,” Circulation. 2003;107:e94-e97.


17. Ibid.

18. Patnaik MM, Moll S. Haemophilia. 2008;14(6):1229-1239.; Wells PS, Blajchman MA,
Henderson P, et al. Am J Hematol. 1994;45:321-324.

19. U.S. National Library of Medicine: Genetics Home Reference, “Your Guide to Understanding Genetic Conditions: Hereditary Antithrombin Deficiency,” https://ghr.nlm.nih.gov/condition/hereditary-antithrombin-deficiency

20. The Clinical Adviser, “Antithrombin Deficiency,” http://www.clinicaladvisor.com/labmed/antithrombin-deficiency/article/614356/

21. Varga, E., et.al., “Prothrombin 20210 Mutation (Factor II Mutation),” Circulation 2004;110;e15-e18. http://circ.ahajournals.org/content/110/3/e15

22. Ibid.

23. Miletich, J., et.al., Absence of Thrombosis in Subjects with Heterozygous Protein C Deficiency, New England Journal of Medicine, 1987;317:991-996

24. U.S. National Library of Medicine: Genetics Home Reference, “Your Guide to Understanding Genetic Conditions: Protein C Deficiency,” https://ghr.nlm.nih.gov/condition/protein-c-deficiency#resources

25. U.S. National Library of Medicine: Genetics Home Reference, “Your Guide to Understanding Genetic Conditions: Protein S Deficiency,” https://ghr.nlm.nih.gov/condition/protein-s-deficiency#genes

26. Mandava, P., et. al., “Drugs and Diseases: Homocystinuria/Homocysteinemia,” Medscape, https://emedicine.medscape.com/article/1952251-overview#a3

27. Piazza, G., “Thrombophilia and Hypercoagulability,” Circulation, 2014;130:e9-e10.


28. Connors, J., “Thrombophilia Testing and Venous Thrombosis,” N Engl J Med 2017;377:1177-87.


29. Ansell, J., “Management of venous thromboembolism: clinical guidance from the Anticoagulation Forum,” J Thromb Thrombolysis, 2016:41:1-2.

30. Vedantham, S., “Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism,” J Thromb Thrombolysis (2016) 41:72.

31. Burnett, A., et. al., “Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment,” J Thromb Thrombolysis, (2016) 41:1.

32. Ibid.

33. Ibid.

34. B Myers, R Neal, O Myers, M Ruparelia, Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning, Obstet Med. 2016 Mar; 9(1): 40–42. Published online 2015 Dec 24. doi: 10.1177/1753495X15621814

Current News

National Blood Clot Alliance Applauds Senator Blunt Rochester’s Call for NFL Blood Clot Protocols; Urges Congress to Fund National Blood Clot Education and Awareness Program

U.S. Senator Lisa Blunt Rochester is calling for an investigation into the NFL's blood clot protocols, raising important questions about player safety, prevention, and medical oversight. The National Blood Clot Alliance weighs in on the need for greater awareness and stronger protections for athletes.

NATIONAL BLOOD CLOT ALLIANCE ADDRESSES QUESTIONS RAISED BY REPORTS ABOUT JALEN HURTS

As Public Interest Grows, the National Blood Clot Alliance Separates Blood Clot Fact From Fiction PHILADELPHIA, PA, UNITED STATES, October…